Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
3.730
+0.140 (3.90%)
At close: Sep 26, 2025, 4:00 PM EDT
3.750
+0.020 (0.54%)
After-hours: Sep 26, 2025, 7:31 PM EDT
Veru Inc. Employees
Veru Inc. had 210 employees as of September 30, 2024. The number of employees increased by 21 or 11.11% compared to the previous year.
Employees
210
Change (1Y)
21
Growth (1Y)
11.11%
Revenue / Employee
$80,412
Profits / Employee
-$155,764
Market Cap
54.65M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VERU News
- 4 days ago - Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity - GlobeNewsWire
- 6 weeks ago - Veru Inc. (VERU) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewsWire
- 6 weeks ago - Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study - GlobeNewsWire
- 7 weeks ago - Veru Announces Reverse Stock Split - GlobeNewsWire
- 2 months ago - Veru to Participate in the 2025 BTIG Virtual Biotech Conference - GlobeNewsWire
- 3 months ago - Veru to Participate in the Virtual BTIG Obesity Health Forum - GlobeNewsWire
- 4 months ago - Veru's Enobosarm Shows Muscle In Wegovy Combo Trial - Benzinga